CO5540301A2 - Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5] dec-2-eno - Google Patents
Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5] dec-2-enoInfo
- Publication number
- CO5540301A2 CO5540301A2 CO03111723A CO03111723A CO5540301A2 CO 5540301 A2 CO5540301 A2 CO 5540301A2 CO 03111723 A CO03111723 A CO 03111723A CO 03111723 A CO03111723 A CO 03111723A CO 5540301 A2 CO5540301 A2 CO 5540301A2
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- aryl
- heterocyclyl
- cycloalkyl
- represent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
Abstract
1.- Derivados sustituidos de 1-oxa-2,8-diaza-espiro[4.5]dec-2-eno con la fórmula general (I) en forma de sus racematos, sus estereoisómeros puros, en especial enantiómeros o diastereómeros, o en forma de mezclas de estereoisómeros, en especial de enantiómeros o diastereómeros, en cualquier relación de mezcla; en forma aislada o en forma de sus ácidos o sus bases, o en forma de sus sales, en especial de las sales fisiológicamente admisibles, y muy en especial se prefiere en forma de sus clorhidratos o en forma de sus solvatos, en especial de los hidratos;en dondeR1 y R2 son independientes entre sí y representan H, alquilo C1-18, cicloalquilo C3-10, (alquilo C1-12)-cicloalquilo C3-10, arilo, (alquilo C1-12)-arilo, heterociclilo, (alquilo C1-12)-heterociclilo o NH-C(=O)-arilo, en donde al menos uno de los grupos R1 y R2 no representa H,o bienlos dos juntos representan -(CR4R5)m-(CR6R7)n-Y-(CR8R9)p-(CR10R11)q- con cada uno de m, n, p y q = 0, 1, 2, 3, 4 o 5, con la condición de que cuando m n = 1 y p q = 1 , o bien representan -CH2-CH2-C(arilo)=CHCH2;R3 representa H, SO2R12 o COR13;R4, R5, R6, R7, R8, R9 R10 y R11 son independientes entre sí y representan H, alquilo C1-10, cicloalquilo C3-8, (alquilo C1-6)-cicloalquilo C3-8, arilo, (alquilo C1-6)-arilo, heterociclilo o C(=O)R14;Y representa CR15R16, NR17 u O;R12 y R13 son independientes entre sí y representan alquilo C1-10, cicloalquilo C3-10, (alquilo C1-6)-cicloalquilo C3-10, arilo, (alquilo C1-6)-arilo, heterociclilo, (alquilo C1-8)-heterociclilo o NR18R19;R14 representa H, alquilo C1-10, cicloalquilo C3-8, (alquilo C1-6)-cicloalquilo C3-8, arilo, (alquilo C1-6)-arilo, heterociclilo, (alquilo C1-6)-heterociclilo o OR20;R15 y R16 son independientes entre sí y representan H, alquilo C1-10, cicloalquilo C3-8, (alquilo C1-6)-cicloalquilo C3-8, arilo, (alquilo C1-6)-arilo, heterociclilo, (alquilo C1-6)-heterociclilo o C(=O)R21;R17 representa H, alquilo C1-10, cicloalquilo C3-8, (alquilo C1-6)-cicloalquilo C3-8, arilo, (alquilo C1-6)-arilo, heterociclilo, (alquilo C1-6)-heterociclilo o C(=O)R22; ...
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10130020A DE10130020A1 (de) | 2001-06-25 | 2001-06-25 | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5540301A2 true CO5540301A2 (es) | 2005-07-29 |
Family
ID=7689008
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO03111723A CO5540301A2 (es) | 2001-06-25 | 2003-12-22 | Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5] dec-2-eno |
Country Status (30)
Country | Link |
---|---|
US (2) | US8048890B2 (es) |
EP (1) | EP1401841B1 (es) |
JP (1) | JP4410554B2 (es) |
KR (1) | KR100917112B1 (es) |
CN (1) | CN1315840C (es) |
AR (1) | AR036098A1 (es) |
AT (1) | ATE302782T1 (es) |
AU (1) | AU2002310768B2 (es) |
BR (1) | BR0211053A (es) |
CA (1) | CA2451859C (es) |
CO (1) | CO5540301A2 (es) |
CZ (1) | CZ20033432A3 (es) |
DE (2) | DE10130020A1 (es) |
DK (1) | DK1401841T3 (es) |
EC (1) | ECSP034924A (es) |
ES (1) | ES2245402T3 (es) |
HK (1) | HK1064669A1 (es) |
HU (1) | HU228774B1 (es) |
IL (2) | IL159544A0 (es) |
MX (1) | MXPA03012013A (es) |
NO (1) | NO332217B1 (es) |
NZ (1) | NZ530689A (es) |
PE (1) | PE20030146A1 (es) |
PL (1) | PL214290B1 (es) |
PT (1) | PT1401841E (es) |
RU (1) | RU2296128C2 (es) |
SI (1) | SI1401841T1 (es) |
SK (1) | SK287390B6 (es) |
WO (1) | WO2003000699A1 (es) |
ZA (1) | ZA200400489B (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10130020A1 (de) | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
PL373956A1 (en) * | 2002-08-14 | 2005-09-19 | Pharmacia & Upjohn Company Llc | Use of reboxetine for the treatment of hot flashes |
DE102004023635A1 (de) * | 2004-05-10 | 2006-04-13 | Grünenthal GmbH | Heteroarylsubstituierte Cyclohexyl-1,4-diamin-Derivate |
DE102005016170A1 (de) * | 2005-04-07 | 2006-10-12 | Grünenthal GmbH | 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
DE102005044814A1 (de) * | 2005-05-19 | 2006-11-23 | Grünenthal GmbH | Substituierte Sprio-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
DE102005044813A1 (de) | 2005-05-19 | 2007-10-04 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
DE102005023784A1 (de) * | 2005-05-19 | 2006-11-30 | Grünenthal GmbH | Substituierte Spiro-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
US9340558B2 (en) | 2007-11-02 | 2016-05-17 | Pain Therapeutics Inc. | Filamin a binding anti-inflammatory and analgesic |
US8653068B2 (en) | 2009-10-30 | 2014-02-18 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
US8614324B2 (en) * | 2008-10-31 | 2013-12-24 | Pain Therapeutics, Inc. | Filamin A binding anti-inflammatory and analgesic |
US8580808B2 (en) * | 2009-10-30 | 2013-11-12 | Pain Therapeutic, Inc. | Filamin A-binding anti-inflammatory analgesic |
WO2010051476A1 (en) * | 2008-10-31 | 2010-05-06 | Pain Therapeutics, Inc. | Filamin a-binding anti-inflammatory analgesic |
US20100279996A1 (en) * | 2009-05-04 | 2010-11-04 | Lindsay Burns Barbier | Novel analgesic that binds filamin a |
WO2010084499A2 (en) * | 2009-01-26 | 2010-07-29 | Israel Institute For Biological Research | Bicyclic heterocyclic spiro compounds |
US8580809B2 (en) * | 2009-10-30 | 2013-11-12 | Pain Therapeutics, Inc. | Filamin A-binding anti-inflammatory analgesic |
US8822464B2 (en) | 2011-11-28 | 2014-09-02 | Boehringer Ingelheim International Gmbh | N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8741892B2 (en) | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8642774B2 (en) * | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
US8796467B2 (en) | 2011-12-13 | 2014-08-05 | Boehringer Ingelheim International Gmbh | Compounds |
US8846948B2 (en) | 2011-12-13 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Compounds |
US8883789B2 (en) | 2011-12-14 | 2014-11-11 | Boehringer Ingelheim International Gmbh | Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors |
US8716277B2 (en) | 2011-12-14 | 2014-05-06 | Boehringer Ingelheim International Gmbh | Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity |
US8937176B2 (en) | 2011-12-14 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Compounds |
US8889677B2 (en) | 2012-01-17 | 2014-11-18 | Boehringer Ingellheim International GmbH | Substituted triazoles useful as mGlu5 receptor modulators |
EP2872899B1 (en) | 2012-07-13 | 2018-07-11 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patient |
JP6417324B2 (ja) | 2012-07-13 | 2018-11-07 | ペイン セラピューティクス インコーポレイテッド | τリン酸化を阻害する方法 |
US9433604B2 (en) | 2013-10-08 | 2016-09-06 | Pain Therapeutics Inc. | Method for inhibiting growth of cancer cells |
LT3402783T (lt) | 2016-01-13 | 2020-05-11 | Grünenthal GmbH | 3-(karboksietil)-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekano dariniai |
SI3402785T1 (sl) | 2016-01-13 | 2020-07-31 | Gruenenthal Gmbh | Derivati 3-(karboksimetil)-8-amino-2-okso-1,3-diaza-spiro-(4.5)-dekana |
JP6917379B2 (ja) | 2016-01-13 | 2021-08-11 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 8−アミノ−2−オキソ−1,3−ジアザ−スピロ−[4.5]−デカン誘導体 |
RS60315B1 (sr) | 2016-01-13 | 2020-07-31 | Gruenenthal Gmbh | Derivati 3-((hetero-)aril)-alkil-8-amino-2-okso-1,3-diaza-spiro-[4.5]-dekana |
AR107434A1 (es) | 2016-01-13 | 2018-05-02 | Gruenenthal Gmbh | Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano |
NZ758117A (en) | 2017-04-12 | 2022-01-28 | Il Dong Pharma | Isoxazole derivatives as nuclear receptor agonists and uses thereof |
CN109793713B (zh) * | 2019-03-26 | 2021-05-28 | 李世系 | 一种用于麻醉的短效催眠镇静的药物组合物及其注射剂制备方法及应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL127065C (es) * | 1964-04-22 | |||
GB1227365A (es) * | 1968-07-29 | 1971-04-07 | ||
JPH02164882A (ja) * | 1988-12-20 | 1990-06-25 | Yamanouchi Pharmaceut Co Ltd | スピロ化合物及びその中間体 |
US5534520A (en) | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
US5073560A (en) * | 1990-07-20 | 1991-12-17 | Fisons Corporation | Spiro-isoxazolidine derivatives as cholinergic agents |
US5849736A (en) * | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
US5739336A (en) | 1995-06-23 | 1998-04-14 | Syntex (U.S.A.) Inc. | 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives |
DE19528472A1 (de) | 1995-08-03 | 1997-02-06 | Boehringer Ingelheim Kg | Neues Verfahren zur Herstellung von Norbenzomorphan einer Zwischenstufe bei Herstellung von pharmazeutisch wertvollen Benzomorphanderivaten, insbesondere von (-)-(1R,5S,S"R)-3'-Hydroxy-2-(2-methoxypropyl-)-5,9,9-trimethyl-6,7 benzomorphan |
EP0854869B1 (en) * | 1995-09-29 | 2004-08-25 | Eli Lilly And Company | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
ZA972195B (en) * | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
EP0888344A1 (en) * | 1996-03-15 | 1999-01-07 | The Du Pont Merck Pharmaceutical Company | Spirocycle integrin inhibitors |
US6214834B1 (en) | 1997-03-28 | 2001-04-10 | Dupont Pharmaceuticals Company | Integrin inhibitor prodrugs |
DE59910360D1 (de) | 1998-11-18 | 2004-09-30 | Basf Ag | Verfahren zur herstellung von 2-alkyl- 3-(4,5- dihydroisoxazol- 3-yl)-halogenbenzolen |
KR20030000243A (ko) | 2001-06-22 | 2003-01-06 | 이 석 민 | 동물사료 제조방법 및 그에 적합한 기밀 플라스틱백발효용기 |
DE10130020A1 (de) | 2001-06-25 | 2003-12-04 | Gruenenthal Gmbh | Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate |
-
2001
- 2001-06-25 DE DE10130020A patent/DE10130020A1/de not_active Withdrawn
-
2002
- 2002-06-19 AR ARP020102303A patent/AR036098A1/es unknown
- 2002-06-21 DK DK02735422T patent/DK1401841T3/da active
- 2002-06-21 JP JP2003507102A patent/JP4410554B2/ja not_active Expired - Fee Related
- 2002-06-21 IL IL15954402A patent/IL159544A0/xx unknown
- 2002-06-21 CN CNB028166825A patent/CN1315840C/zh not_active Expired - Fee Related
- 2002-06-21 AT AT02735422T patent/ATE302782T1/de active
- 2002-06-21 RU RU2004100823/04A patent/RU2296128C2/ru not_active IP Right Cessation
- 2002-06-21 CA CA2451859A patent/CA2451859C/en not_active Expired - Fee Related
- 2002-06-21 EP EP02735422A patent/EP1401841B1/de not_active Expired - Lifetime
- 2002-06-21 HU HU0400810A patent/HU228774B1/hu not_active IP Right Cessation
- 2002-06-21 MX MXPA03012013A patent/MXPA03012013A/es active IP Right Grant
- 2002-06-21 NZ NZ530689A patent/NZ530689A/en not_active IP Right Cessation
- 2002-06-21 CZ CZ20033432A patent/CZ20033432A3/cs unknown
- 2002-06-21 AU AU2002310768A patent/AU2002310768B2/en not_active Ceased
- 2002-06-21 DE DE50204037T patent/DE50204037D1/de not_active Expired - Lifetime
- 2002-06-21 BR BR0211053-9A patent/BR0211053A/pt not_active IP Right Cessation
- 2002-06-21 SK SK1570-2003A patent/SK287390B6/sk not_active IP Right Cessation
- 2002-06-21 SI SI200230221T patent/SI1401841T1/sl unknown
- 2002-06-21 ES ES02735422T patent/ES2245402T3/es not_active Expired - Lifetime
- 2002-06-21 WO PCT/EP2002/006880 patent/WO2003000699A1/de active IP Right Grant
- 2002-06-21 PT PT02735422T patent/PT1401841E/pt unknown
- 2002-06-21 PL PL367748A patent/PL214290B1/pl not_active IP Right Cessation
- 2002-06-21 PE PE2002000537A patent/PE20030146A1/es not_active Application Discontinuation
- 2002-06-21 KR KR1020037016835A patent/KR100917112B1/ko not_active IP Right Cessation
-
2003
- 2003-12-19 NO NO20035730A patent/NO332217B1/no not_active IP Right Cessation
- 2003-12-22 CO CO03111723A patent/CO5540301A2/es active IP Right Grant
- 2003-12-22 EC EC2003004924A patent/ECSP034924A/es unknown
- 2003-12-24 IL IL159544A patent/IL159544A/en not_active IP Right Cessation
- 2003-12-24 US US10/744,082 patent/US8048890B2/en not_active Expired - Fee Related
-
2004
- 2004-01-22 ZA ZA200400489A patent/ZA200400489B/en unknown
- 2004-09-30 HK HK04107516A patent/HK1064669A1/xx unknown
-
2011
- 2011-05-26 US US13/116,578 patent/US8557796B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5540301A2 (es) | Derivados sustituidos del 1-oxa-2,8-daza-espiro[4,5] dec-2-eno | |
PE20030703A1 (es) | Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3 | |
NO20050065L (no) | Kjemiske forbindelser | |
CA2256582A1 (en) | Oxa acids and related compounds for treating skin conditions | |
AR017729A1 (es) | Composicion y procedimientos para el tenido de las fibras queratinicas y en particular de las fibras queratinicas humanas tales como los cabellos y un dispositivo de varios compartimientos o kit de tenido de varios compartimientos. | |
HUP0202799A2 (hu) | Herbicid hatású izoxazolinszármazékok és azt tartalmazó készítmény | |
AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
DK1585493T3 (da) | Triazinderivater som UV-absorbenter | |
DE59610509D1 (de) | Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz | |
GEP20115347B (en) | Heterocyclocarboxamide derivatives | |
AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
CO4520230A1 (es) | Derivados de [3-(4-fenilpiperacin-1-il) propilamino, tio y oxilo]-piridina, pirimidina y benceno como antagonistas de alfa 1- adrenoceptores | |
WO2004052837A3 (en) | Amino substituted hydroxyphenyl benzophenone derivatives | |
TW375614B (en) | New aryl-glycin-amide derivatives, process for preparing them and pharmaceutical compositions containing these compounds | |
PL319104A1 (en) | 2,3-dihydro-1-(2,2,2-trifluoroethly0)-2-oxo-5-phenyl-1h-1,4-benzodiazepinmes | |
AR034588A1 (es) | Derivados heterociclilalcoxi-, -alquiltio- y -alquilamino-benzazol como ligandos de 5-hidroxitriptamina-6, un proceso para su preparacion, intermediarios, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos | |
TR199802039T2 (xx) | Yeni alfa-hidroksilik asit t�revleri, �retimleri ve kullan�mlar�. | |
GR3002051T3 (en) | 3-oxadiazolyl and 3-carboxylic-acid beta-carboline derivatives, their preparation and their use as medicaments | |
MX9801292A (es) | Derivados de benzoilo. | |
TW340109B (en) | Amide derivatives and their therapeutic use | |
AP9701048A0 (en) | Parasiticidal pyrazoles. | |
DE3686723D1 (de) | Oxadiazolylacetonitrile, ihre herstellung und anwendung. | |
ATE218538T1 (de) | Azahexan-derivate als substratisostere von retroviralen aspartat-proteasen | |
DE69116788D1 (de) | 4-substituierte Dihydropyrido [4,3-d] pyrimidine als Analgetika und entzündungshemmende Mittel zur topischen Anwendung bei der Behandlung von Hauterkrankungen | |
NO20003784L (no) | FremgangsmÕte for fremstilling av enansiomert rene cykloalkanoindolkarboksylsyre og azaindolkarboksylsyrer og pyrimido 1,2a indolkarboksylsyrer og derivater derav |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |